Prognostic factors for anaplastic astrocytomas

Area of Science:

• Neuro-oncology
• Molecular Pathology
• Cancer Biology

Background:

• Anaplastic astrocytomas (WHO grade III) represent 10% of gliomas, characterized by unclear biologic behavior and variable outcomes.
• Limited definitive data exists on predictive and prognostic factors, making them an enigmatic entity in astrocytic tumors.
• Current prognostic indicators are restricted to age and Karnofsky Performance Status.

Purpose of the Study:

• To review and highlight emerging biological prognostic factors for anaplastic astrocytoma.
• To identify potential therapeutic targets based on novel biomarkers.
• To discuss the significance of gene expression profiles and imaging characteristics in predicting prognosis.

Main Methods:

• Literature review of studies investigating prognostic factors in anaplastic astrocytoma.
• Analysis of potential biomarkers including tumor suppressor genes (e.g., RB1 pathway, PTEN), angiogenic factors (e.g., HIF-1α, VEGF), and DNA repair genes (e.g., MGMT methylation).
• Inclusion of recent findings on magnetic resonance imaging (MRI) characteristics (necrosis, enhancement) and gene expression profiling.

Main Results:

• Several potential biomarkers are emerging, including genes on chromosomes 9q and 7, PTEN, survivin, and formylpeptide receptor.
• Angiogenic factors like hypoxia-inducible factor-1alpha and vascular endothelial growth factor show prognostic significance.
• MGMT gene methylation status and MRI features like necrosis and enhancement are novel putative determinants of prognosis.

Conclusions:

• Knowledge regarding anaplastic astrocytoma prognosis remains limited, necessitating further research.
• Gene expression profiling holds promise for understanding tumor biology and identifying therapeutic targets.
• A multi-faceted approach combining molecular markers and imaging is crucial for improving patient outcomes.